Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Pygeum vs Saw Palmetto: they're closely matched on evidence (5.5 vs 4/10); they're alternatives for prostate health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Pygeum and Saw Palmetto are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Too few graded studies
1 of 2 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (3)
Outcomes where both Pygeum and Saw Palmetto have evidence — compare verdict strength side-by-side.
75-100 mg standardized extract daily. The one cited trial that states a dose used 100 mg a day. Label products go up to 200 mg, above that dose.
Once or twice daily, With or without food
Standardized extract (13-14% sterols)
320mg standardized extract (85-95% fatty acids) (no cited trial states the dose it used)
With meals
Liposterolic extract (standardized to 85-95% fatty acids)
6-8 weeks
6-8 weeks
8-12 weeks
4-12 weeks
4-12 weeks
What do we know about phytotherapy of benign prostatic hyperplasia?
Life sciences (2015) · Review
On the basis of preclinical studies several mechanisms of action have been postulated, including 5alpha-reductase inhibition, alpha-adrenergic antagonism, dihydrotestosterone and estrogen receptor inhibition.
Phytotherapy of benign prostatic hyperplasia. A minireview
Phytotherapy research : PTR (2014) · Review
Histological BPH, which typically develops after the age of 40 years, ranges in prevalence from >50% at 60 years to as high as 90% by 85 years of age.
Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS)
BMJ clinical evidence (2011) · Systematic review
We found 63 systematic reviews, RCTs, or observational studies that met our inclusion criteria.
Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials
European urology focus (2021) · Meta analysis · n=8564
In this network meta-analysis, we demonstrated that SeR did not show clinically meaningful improvement in LUTS and PF.
Efficacy and safety of a hexanic extract of Serenoa repens (Permixon) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies
BJU International (2018) · Meta analysis · n=5800
Data from 27 studies (15 RCTs and 12 observational studies) were included for meta-analysis. Articles studying S. repens extracts other than Permixon were excluded.
Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement.
The Cochrane database of systematic reviews (2023) · Systematic review · n=4656
We included 27 studies (of which 9 were new) involving a total of 4656 participants, 19 studies comparing Serenoa repens with placebo, and 8 studies comparing Serenoa repens in combination with other phytotherapeutic agents versus placebo.
All points come from the CAMUS trial in 369 men with urinary symptoms from an enlarged prostate, which raised an ethanolic extract from 320 to 640 to 960 mg a day over 72 weeks (PMID 21954478). At no dose was saw palmetto better than placebo for the symptom score or any secondary outcome, peak urinary flow included, so every point is plotted as no effect. The same trial found no toxicity and no dose-related adverse effects up to 960 mg a day over 18 months (PMID 23063633). A meta-analysis limited to the hexanic extract Permixon reported a higher peak flow than placebo (PMID 29694707), a different extract from the one CAMUS tested.
AI-estimated from published studies. Interpret as directional guidance.
Both Pygeum and Saw Palmetto are closely matched — the best choice depends on your specific health goals.
For prostate health, Pygeum has a higher relevance score (80 vs 32).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.